Faculty of Pharmaceutical Sciences, Department of Pharmacy, University of Sao Paulo, Avenida Professor Lineu Prestes 508, Butantan, 05508-900 Sao Paulo, SP, Brazil.
Faculty of Pharmacy, Department of Pharmaceutical Sciences, Federal University of Juiz de Fora, Rua José Lourenço Kelmer, s/n, Campus Universitário, Juiz de Fora, 36036-900 Minas Gerais, Brazil.
Int J Pharm. 2022 Jun 10;621:121782. doi: 10.1016/j.ijpharm.2022.121782. Epub 2022 Apr 28.
According to the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), bacterial infections are one of the greatest threats to global health, food production, and life expectancy. In this sense, the development of innovative formulations aiming at greater therapeutic efficacy, safety, and shorter treatment duration compared to conventional products is urgently needed. Lipid-based nanocarriers (LBNs) have demonstrated the potential to enhance the effectiveness of available antibiotics. Among them, liposome, nanoemulsion, solid lipid nanoparticle (SLN), and nanostructured lipid carrier (NLC) are the most promising due to their solid technical background for laboratory and industrial production. This review describes recent advances in developing antibiotic-loaded LBNs against susceptible and resistant bacterial strains and biofilm. LBNs revealed to be a promising alternative to deliver antibiotics due to their superior characteristics compared to conventional preparations, including their modified drug release, improved bioavailability, drug protection against chemical or enzymatic degradation, greater drug loading capacity, and biocompatibility. Antibiotic-loaded LBNs can improve current clinical drug therapy, bring innovative products and rescue discarded antibiotics. Thus, antibiotic-loaded LBNs have potential to open a window of opportunities to continue saving millions of lives and prevent the devastating impact of bacterial infection.
根据世界卫生组织（WHO）和疾病控制与预防中心（CDC）的数据，细菌感染是对全球健康、粮食生产和预期寿命的最大威胁之一。在这种情况下，迫切需要开发创新性制剂，以提高治疗效果、安全性，并缩短治疗时间，与传统产品相比。基于脂质的纳米载体（LBNs）已被证明有潜力增强现有抗生素的效果。其中，脂质体、纳米乳剂、固体脂质纳米粒（SLN）和纳米结构脂质载体（NLC）由于具有实验室和工业生产的坚实技术背景，是最有前途的。这篇综述描述了开发针对敏感和耐药细菌菌株和生物膜的载抗生素 LBN 的最新进展。与传统制剂相比，LBN 具有改良的药物释放、提高的生物利用度、防止药物化学或酶降解、更高的药物载量和生物相容性等卓越特性，因此被认为是输送抗生素的有前途的替代物。载抗生素的 LBN 可以改善当前的临床药物治疗，带来创新产品并挽救被废弃的抗生素。因此，载抗生素的 LBN 有可能为继续拯救数百万人的生命和防止细菌感染的破坏性影响开辟机会之窗。
